Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
書誌事項
- 公開日
- 2019-07
- 権利情報
-
- https://www.elsevier.com/tdm/userlicense/1.0/
- https://www.elsevier.com/legal/tdmrep-license
- DOI
-
- 10.1016/s2213-8587(19)30192-5
- 公開者
- Elsevier BV
この論文をさがす
収録刊行物
-
- The Lancet Diabetes & Endocrinology
-
The Lancet Diabetes & Endocrinology 7 (7), 515-527, 2019-07
Elsevier BV
